Anlon Healthcare LtdQ1 FY27
Anlon Healthcare Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹15.1P/E: 24.4Market Cap: ₹770 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2.
- →Current optimal capacity utilization is around 65-70%, with peak revenue potential from existing assets at ₹350-400 crore.
- →Expansion underway at Anlon with a ₹130 crore CAPEX; capacity expected to increase by 1200 metric tonnes (from 400 to approx. 1600 metric tonnes).
- →New capacity at Anlon expected to commission by Q1 FY28, aiming to drive FY28 revenue to approximately ₹700 crore.
- →For FY27-28, standalone Anlon sales expected to remain around ₹180 crore, as it is operating near peak capacity.
- →Growth also supported by subsidiaries Apiqo and BizoƟc, both profitable with increasing capacities and business opportunities.
- →New product launches planned in peptides and pain management (cosmetic peptides and ointments) with production starting by FY28.
- →CDMO projects progressing, with commercial supply expected from Q3 FY27 and FY28.
- →Overall, the company is cautiously optimistic, maintaining conservative PAT margins of 12-13% for FY27-28 amid expansion-related uncertainties.
Margin guidance
Category 3- →PAT margin expected for FY27 and FY28 is around 12-13%, considered conservative due to potential expansion delays. (Page 16)
- →EBITDA margin expected to normalize to 25-27% for FY27, improving from Q1 dip caused by raw material price shocks; FY28 margins expected to maintain or slightly improve. (Pages 9, 12, 13)
- →Revenue guidance for FY27 maintained at ₹350-400 crore; projected to grow to around ₹700 crore in FY28 after planned capacity expansion. (Pages 5, 6, 12)
- →Expansion includes adding ~1200 MT capacity at Anlon site, expected commissioning by Q1 FY28. (Pages 5, 6, 13)
- →Standalone Anlon revenue expected around ₹180 crore for FY27; Apiqo and Bizotic subsidiaries contributing ₹120-150 crore and ₹60 crore respectively in FY27. (Pages 6, 9, 16)
- →CDMO and peptide manufacturing initiatives underway, with commercial activities expected from FY28 onwards, potentially contributing to future growth. (Page 12)
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company is taking debt of around ₹70 crore for the new CAPEX related to Anlon's expansion (Page 13).
- →The total CAPEX planned is around ₹130 crore; the remaining amount will be funded internally (Page 15).
- →There is no mention of immediate equity dilution or fundraising through equity at this time (Page 13, 11).
- →Management is open to inorganic growth opportunities if aligned with strategy but currently focusing on consolidating recent acquisitions (Page 11).
- →Debt is kept low, with least leverage across companies, indicating cautious financing approach (Page 11).
- →No confirmed plans for further fundraising beyond the stated debt for CAPEX as of now.
Order book
- →The transcript does not explicitly mention a specific current or expected order book value for Anlon Healthcare Limited.
- →It is indicated that the company has long-term relationships with 10 to 15 key B2B customers.
- →Pricing and payments are based on these long-term contracts, with payment terms generally around 90 days but actual receipts sometimes extending to 130-135 days.
- →The company is focusing on strict payment terms and not working with customers who delay payments to improve receivables.
- →Expansion plans and capacity increases indicate healthy future demand: new capacities expected to start contributing to revenue by Q1 FY28.
- →For Q1 FY27, acquisitions Apiqo and BizoƟc contributed revenues (~45 CR and 12 CR respectively), indicating ongoing business activity.
- →Exact pending orders or order book figures as of 30th July or current date were not provided but can be obtained on request from the finance team (contact Parth suggested).
Capex plans
Yes- →Current CAPEX for expansion is around ₹130 crore focused on Anlon's standalone capacity expansion.
- →The expansion will increase Anlon's capacity by approximately 1,200 metric tons (from current 400 to 1,600 metric tons).
- →Construction and statutory approvals are underway, with expected commissioning by Q1 FY28 (subject to regulatory timelines).
- →Debt financing of around ₹70 crore is planned for this CAPEX, with the remainder funded internally.
- →Anlon Biologics subsidiary is being established for peptides and biologics manufacturing, with operations expected to start generating revenue by FY28 Q4.
- →Anlon Medicare, focusing on surgical implants for trauma and orthopedic applications, is expected to generate revenue from FY28 Q2.
- →Growth driven by these expansions anticipates increasing revenue potential to about ₹700 crore by FY28.
- →The company is exploring further inorganic growth opportunities aligned with its strategic goals but currently focusing on consolidation of recent acquisitions.
How does Anlon Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Anlon Healthcare Ltd
Rev 2Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Anlon Healthcare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Anlon Healthcare Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.